Let’s get started. Request an appointment online.

Let’s get started.

Request an appointment online.

About

Dr Randeep Singh

Medical & Hemato Oncologist

MD, DM, ECMO, FCCP

Medical Reg : Medical Council , No 32096

Current Employment

  • Director Oncology Services at NARAYANA Hospital, Gurugram w.e.f April 2025

Education & Qualification

  • Advanced certification in Molecular oncology 2023
    ( Sidney Kimmel Cancer Centre :Philadelphia)
  • ECMO (European Certified Medical Oncology) 2011
  • DM (Medical Oncology), Tata Memorial Centre, Mumbai 2011
  • MD (Pediatrics), Rajasthan University 2006
  • MBBS, Bharati Vidyapeeth Deemed University. Pune 2000

 A highly experienced cancer specialist, he brings over 20 years of focused practice in oncology to his patients. Dr. Singh offers state-of-the-art cancer treatments – including chemotherapy, targeted therapy and immunotherapy – tailored to each patient’s needs. He holds advanced medical qualifications (MD and DM in Medical and Hemato-oncology) and completed specialized training at Mumbai’s prestigious Tata Memorial Hospital. In addition to his clinical work, Dr. Singh is a leader in the oncology community: he serves as Editor Emeritus of an International molecular oncology journal and as a executive member of major oncology organizations (such as the Indian Cooperative Oncology Network, ESMO, and ASCO)[4]. This combination of deep expertise and continual professional engagement helps him stay at the forefront of cancer care and research.

Expertise & Qualifications

  • Comprehensive Cancer Care: Singh’s areas of specialization include the treatment of breast, lung, gastrointestinal and blood cancers, among others. His services cover modern chemotherapy protocols, precision-targeted therapies, and the latest immunotherapy techniques.
  • Advanced Training: He earned his MBBS in 2000 and completed an MD (2006) followed by a DM in Medical Oncology at Tata Memorial Hospital (2011). In short, Dr. Singh combines a broad medical foundation with highly specialized oncology training.
  • Professional Leadership: He currently serves as Director of Oncology Services at Narayana Health , Gurugram since 2025.

Compassion and empathy are core to Dr. Singh’s approach. He works within a multidisciplinary cancer team that emphasizes patient-first care. Narayana’s cancer center is nationally recognized for “state-of-the-art treatments” delivered with “compassionate care and a multidisciplinary approach”. In keeping with this ethos, Dr. Singh ensures every patient understands their treatment plan and feels supported throughout their journey. He and his team provide extensive patient education, pain management and emotional support – often involving palliative care specialists – so that patients and families receive help for both medical and psychological needs.

Through this blend of clinical expertise, advanced qualifications, and genuine compassion, Dr. Randeep Singh offers outstanding cancer care. Patients trust his team for personalized, expert treatment and supportive care every step of the way. 

Previous Employments/ Work Experience

  • Director & Senior Consultant Medical & Hemato – oncologist at NARAYANA hospital, Gurugram July 2019 – April 2025
  • SR. Consultant and Unit Head Medical oncologist at ARTEMIS HOSPITALS MARCH 2017 to JUNE 19
  • HOD & SR. Consultant Medical & Hemato-oncologist at HCG CANCER CENTRE DELHI: FEB 2016- Feb 2017.
  • Consultant Medical Oncologist at Max Cancer Centre, Delhi from April 2012 to February 2016
  • Consultant in the Dept. of Medical Oncology; Tata Memorial Centre, Mumbai from 1st Aug 2011 till 1st April 2012.
  • Senior residency (SR) in Dept. of Medical Oncology; Tata Memorial Centre, Mumbai from 1st August 2008 till 31st July 2011.
  • Senior residency (SR) in Dept. of General Pediatrics; PGIMER Chandigarh from 1st Jan 2007 till 30th Sept 2007.
  • Junior Residency (JR) in Dept. of Pediatrics; Dr S.N. Medical College. Jodhpur from 1st May 2003 till 31st April 2006.

Awards & Prizes

  • 2014 by Indian cooperative oncology network (ICON) for 2nd in Geriatric oncology case presentation
  • 2011 by Mumbai Hematology Group for 2nd in DM hematology quiz at national level.
  • 2006 by National Neonatology Forum for 1st in neonatology quiz at state level.
  • 2006 by Indian Academy pediatrics for 1st in post graduate quiz at state level.
  • 2006 by Indian Academy pediatrics for 2nd in paper presentation at state level.
  • 2005 by Indian Academy pediatrics for 1st in post graduate quiz at state level.
  • 2000 distinction awarded in surgery and ophthalmology by BVDU, Pune.
  • 1997 distinction awarded in biochemistry by BVDU, Pune.

Professional Societies Membership

  • Indian Co-operative Oncology Network (ICON) from 2011 till date
  • European society of medical oncology (ESMO) from 2011 till date
  • American society of clinical oncology (ASCO) from 2010 till date
  • Indian academy of pediatrics (IAP) from 2003 till 2008
  • Jt. SECRETARY Indian Society Medical & pediatric Oncology. JAN 2014 till Jan 2022
  • Co- Founder Member of International CME Oncology w.e.f June 2014
  • Executive member of Delhi NCR Oncology GROUP w.e.f April 2015 till Dec 2021
  • Executive member of Indian Cooperative Oncology Network (ICON) , July 2015.
  • Editor International Journal of Molecular and Immuno Oncology ( IJMIO) w.e.f from Nov 2016
  • Organizing secretary for National conference of ISMPO, 2016 (ISMPOCON).
  • Organizing secretary for National conference of Molecular oncology , 2019 (MOSCON).
  • Organizing secretary for Delhi Oncology Forum Annual Meeting 2019 at Delhi.
  • Organizing chairperson for National conference of Molecular oncology , 2020 (MOSCON).

Professional Interest

  • Lung Cancer
  • Breast Cancer
  • Gastrointestinal Malignancies

Research/ Thesis Work

  • A retrospective analysis of clinical characteristics and outcome of children with acute myeloid leukemia and impact of addition of maintenance therapy to standard induction and consolidation.
  • Analysis of children and young adults with acute biphenotypic leukemia at Tata Memorial Centre, Mumbai.
  • A Retrospective analysis of long-term outcome of pediatric autologous and allogenic transplantation at Tata Memorial Centre, Mumbai.
  • A prospective evaluation the safety and efficacy of ab arteether in uncomplicated falciparum malaria in children.

Publications

1.  Bhawna Sirohi, Sissmol Davis, Anu R I, Moushumi Suryavanshi, Shaheenah S. Dawood, Randeep Singh, Deborah Mukherji, Ramila Shilpakar, Sujith Kumar Mullapally, Aju Mathew. Importance of clinical decision making in precision oncology: Discordance in recommendation between next generation sequencing test vendor and molecular tumour board in India. Journal of Clinical Oncology 2023 41:16_suppl, e15050.

2.  Parikh, P., Babu, G., Singh, R. et al. Consensus guidelines for the management of HR-positive HER2/neu negative early breast cancer in India, SAARC region and other LMIC by DELPHI survey method. BMC Cancer 23, 714 :2023.

3.  Kaur S, Garg H, Nandwani M, Kalita M, Bansal S, Singh R. Influence of New FIGO 2018 Staging on Treatment Outcomes in Early-Stage Cervical Cancer: A Single-Center Study. South Asian J Cancer. 2022 Jun 25;11(3):213-217.

4.  Darling HS, Parikh P, Vaishnav R, Verma A, Gulia A, Kapoor A, Singh R . Severe acute respiratory syndrome coronavirus 2: Mutations and variants of concern – the Indian scenario. Int J Mol Immuno Oncol 2021;6(2):6671.

5.  Parikh PM, Kapoor A, Joshi K, Bansal I, Vamshi K, Sahoo TP, Singh R, et al. Advanced lung cancer and molecular testing in the middle of COVID-19 second wave in the SAARC region. Int J Mol Oncol 2021 , May-june

6.  Thirumalairaj R, Parikh P. M, Agarwal A, Singh R et al. South Asian Declaration – Consensus Guidelines for COVID-19 vaccination in cancer patients. South Asian J Cancer. 2021 ;10(1):3-8.

7.  Parikh PM, Singh R . Why we should rely only on molecular tests based on Indian data.Int J Mol Oncol 2020;5(2): 44- 46.

8.  Kaur S, Singh R . Patterns of care for ovarian cancer.. Cancer Res Stat Treat 2019; 2 :217-220.

9.  Parikh PM, Wadhwa J, Minhas S, Gupta A, Mittal S, Singh R, et al. Practical consensus recommendation on when to do BRCA testing.. South Asian J Cancer 2018;7 (2),106 – 9.

10.  Gupta S, Chatterjee S, Nigade J, Aggarwal S, Singhal M, Singh R et al. Current treatment options for human epidermal growth factor receptor 2-directed therapy in metastatic breast cancer: An Indian perspective. et al. Ind J Med Paed Oncol 2018; 39(3): 368-79.

11.  Bahl A, Singh R, Wadhwa J, Gupta S, Ahmed M, P. N. Uppal . Practical consensus recommendations regarding the management of HER2 neu positive early breast cancer cancer .. South Asian J Cancer 2018;7,102 – 5.

12.  Gujree MA, Singh R Liquid Biopsy : An innovation of the modern medicine Int J Mol Immuno Oncol 2017; 2: 30-32.

13.  Rohtagi N, Singh R . Clinicopathological and Molecular Epidemiological Study of Lung Cancer Patients seen at a Tertiary Care Hospital in Northern India.. South Asian J Cancer 2017.

14.  Singh R, Gupta S . Small HER2 Positive Breast Cancer: When is not enough?. Ind J Med & Paediatr Oncol 2017.

15.  Batra U, Parikh PM, Prabhash K, Tongaonkar HB, Chibber P, Dabkara D, Singh R et al. Oncology Gold StandardTM practical consensus recommendations 2016 for treatment of advanced clear cell renal cell carcinoma. South Asian J Cancer 2016; 5: 167-75.

16.  Bhattacharyya GS, Malhotra H, Govindbabu K, Singh R, Vora A, Sahoo TP. Assesment of Renal Function among Patients with bone metastasis . Journal of Geriatric Oncology 2016; 7(6): S 1- Abstract 1226.

17.  Parikh PM, Ranade AA, Govind B, Ghadyalpatil N, Singh R, Bharath R et al. Lung cancer in India: Current status and promising strategies. South Asian Journal of Cancer. 2016; 5(3): 93-95.

18.  Singh R, Shirali R, Chatterjee S, Adhana A, Arora RS. Epidemiology of cancers among adolescents and young adults from a tertiary cancer center in Delhi. Ind J Med & Paediatr Oncol 2016 ; 37 [2]: 90 – 94.

19.  Singh R, Jain S, Chabbra R, Naithani R, Upadhyay A,Walia M. Characterization and anti-microbial susceptibility of bacterial isolates: Experience from a tertiary care cancer center in Delhi. Ind J Cancer 2014: 51(4); 477- 480.

20.  Banavali S, Singh R, Prasad M et al . Is there a role for a novel maintenance therapy in pediatric patients with AML? Pediatr Blood Cancer 2011;57:770

21.  Singh R, Dwivedi P, Dongre A, Arora B, Gujral S, Subramanian PG, Nahar A, Kurkure P, Banavali S. Outcome of acute biphenotypic leukemia in children and young adults. Paed Blood cancer 2010; 55 (5): abstr PB 001.

22.  Singh R, Joshi A, Bagal B, Kannan S, Banavali S, Nair R, Khattry N. Long-term outcome of pediatric allogenic transplantation from Tata Memorial Centre, Mumbai. J. Clin Oncol 2010; 28(S- 15): abstr 17000.

23.  Bagal B, Joshi A, Shah M, Singh R, Kannan S, Menon H, Banavali S, Nair R, Khattry N. Results of Hematopoietic stem cell transplantation in acute myeloid leukaemia over 25 years from a cancer treatment center, Mumbai. Bone Marrow Transplant 2010; 45 (S-2): abstr 429.

24.  Ghadyalpatil N, Prabhash K, Menon H, Nair R, Banavali S, Noronha V, Wabale V, Singh R, Goyal G, Ostwal V. Tuberculosis infection in chronic myeloid leukemia (CML) patients treated with imatinib. J. Clinical Oncology 2010; 28(S-15): abstr 6594.

25.  Noronha V, Raut NV, Prabhash K, Agarwal J, Pramesh C, Dikshit R, Karimundackal G, Munshi A, Purandare N, Singh R. Epidemiology of lung cancer in India: Is there a change in trends here too? J. Clin Oncol 2010; 28(S-15): abstr 12028.

26.  Joshi A, Singh R, Shah MS, Umesh S, Khattry N.Subcutaneous mycosis and fungemia by Aureobasidium pullulans: a rare pathogenic fungus in a post allogeneic BM transplant patient. Bone Marrow Transplantation (2010) 45, 203–204.

27.  Ghadyalpatil N, Banawali S, Kurkure P, Arora B, Bansal S, Amare P, Choughule A, Soy L, Singh R. Efficacy and tolerability of imatinib mesylate in pediatric chronic myeloid leukemia in a large cohort: Results from a tertiary care referral center in India. J Clin Oncol 2009; 27(S-15); abstr 10047.

28.  Singh R, Joshi A, Bagal B, Kannan S, Khattry N. Results of Autologous Transplants in Pediatric patients (<18 yrs) from Tata Memorial Centre, Mumbai. . MHG abstract book 2009; p09.

29.  Bagal B, Kumar N, Singh R, Joshi A, Kannan S, Khattry N. Results of autologus transplants for lymphomas from Tata Memorial Centre, Mumbai. MHG abstract book 2009; p 07.

30.  Bagal B, Joshi A, Shah M, Singh R, Khattry N. Results of Hematopoietic Stem cell Transplantion in Acute Myeloid Leukemia from Tata Memorial Center. MHG abstract book 2009; p 11.

31.  Joshi A, Bagal B, Kumar N, Singh R, Khattry N. Comparison of toxicity of BEAM vs. LACE regimen in patients of lymphoma. MHG abstract book 2009; p 13.

32.  Akhade A, Singh R, Raut N, Sengar M, Amre P, Mani S, Menon H. Novel sequential treatment approach with Arsenic trioxide as induction therapy in newly diagnosed APML patients. MHG Abstract Book 2008.